Conference Proceedings

Phase 1/2 open-label trial to assess the safety and preliminary efficacy of Lu-177-OPS201 as peptide receptor radionuclide therapy in patients with somatostatin receptor-positive, progressive neuroendocrine tumours

G Nicolas, RP Baum, K Herrmann, M Lassmann, RJ Hicks, AR Haug, S Navalkissoor, H Oberwittler, T Wang, D Wild

EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING | SPRINGER | Published : 2017